Harvard Bioscience, Inc.
HBIO
$5.37
-$0.18-3.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 15.27% | 0.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 15.27% | 0.69% | |||
| Cost of Revenue | 11.59% | -3.89% | |||
| Gross Profit | 17.89% | 4.23% | |||
| SG&A Expenses | -11.09% | -0.14% | |||
| Depreciation & Amortization | -0.58% | -26.42% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.31% | -3.43% | |||
| Operating Income | 1,257.14% | 139.58% | |||
| Income Before Tax | -182.54% | 49.69% | |||
| Income Tax Expenses | -468.04% | 246.43% | |||
| Earnings from Continuing Operations | -131.28% | 46.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -131.28% | 46.06% | |||
| EBIT | 1,257.14% | 139.58% | |||
| EBITDA | 197.96% | 57.37% | |||
| EPS Basic | -131.02% | 46.36% | |||
| Normalized Basic EPS | -174.85% | 47.45% | |||
| EPS Diluted | -112.77% | 41.76% | |||
| Normalized Diluted EPS | -174.85% | 47.45% | |||
| Average Basic Shares Outstanding | 0.10% | 0.57% | |||
| Average Diluted Shares Outstanding | 0.10% | 0.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||